VNDA Research and Charts

VNDA - Vanda Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-06-30)

Last 4.72	Change ⇓ -0.06 (-1.26%)	Volume 375,217
	Open 4.78	High 4.83	Low 4.71

8EMA (Daily) 4.66	40EMA (Daily) 4.49	50EMA (Daily) 4.48	STO (Daily) 62.305	MACD Hist (Daily) 0.044
8EMA (Weekly) 4.555	40EMA (Weekly) 4.62	50EMA (Weekly) 4.69	STO (Weekly) 65.317	MACD Hist (Weekly) 0.124


Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.